Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker)

2004 ◽  
Vol 93 (2-3) ◽  
pp. 105-111 ◽  
Author(s):  
Konstantinos Dimopoulos ◽  
Tushar V. Salukhe ◽  
Andrew J.S. Coats ◽  
Jamil Mayet ◽  
Massimo Piepoli ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Mortality And Morbidity ◽  
Β Blocker ◽  
Meta Analyses

scholarly journals Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure

Circulation ◽  
2001 ◽  
Vol 103 (1) ◽  
pp. 148-154 ◽  
Author(s):  
Shokei Kim ◽  
Minoru Yoshiyama ◽  
Yasukatsu Izumi ◽  
Hitomi Kawano ◽  
Manabu Kimoto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Function ◽  
Cardiac Remodeling ◽  
Rat Heart ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Receptor

scholarly journals Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure

Circulation ◽  
2003 ◽  
Vol 108 (11) ◽  
pp. 1306-1309 ◽  
Author(s):  
Jay N. Cohn ◽  
Inder S. Anand ◽  
Roberto Latini ◽  
Serge Masson ◽  
Yann-Tong Chiang ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Sustained Reduction

Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure

2004 ◽  
Vol 287 (6) ◽  
pp. H2487-H2492 ◽  
Author(s):  
Kaoru Funabiki ◽  
Katsuya Onishi ◽  
Kaoru Dohi ◽  
Takafumi Koji ◽  
Kyoko Imanaka-Yoshida ◽  
...  
Keyword(s):  
Heart Failure ◽  
Myocardial Fibrosis ◽  
Angiotensin Receptor Blocker ◽  
Ace Inhibitor ◽  
Candesartan Cilexetil ◽  
Left Ventricular ◽  
Receptor Blocker ◽  
Mrna Levels ◽  
Angiotensin Receptor ◽  
Rapid Pacing

Angiotensin receptor blocker (ARB) and angiotensin-converting enzyme (ACE) inhibitor (ACEI) each act in a different manner to prevent myocardial fibrosis and left ventricular (LV) stiffness in animals with pathways in the heart for generating ANG II as well as ACE. A model of pacing-induced congestive heart failure (CHF) was used to test the central hypothesis that ARB + ACEI prevents myocardial fibrosis and decreases LV stiffness to a greater extent than ARB or ACEI alone. Thirty-five dogs were assigned to the following treatment protocols on the 8th day of a 4-wk pacing schedule: 1) rapid ventricular pacing, 2) ARB (candesartan cilexetil, 1.5 mg·kg−1·day−1) with pacing, 3) ACEI (enalapril, 1.9 mg·kg−1·day−1) with pacing, 4) ARB (candesartan cilexetil, 0.75 mg·kg−1·day−1) + ACEI (enalapril, 0.95 mg·kg−1·day−1) with pacing, and 5) sham operation. The LV stiffness coefficient was significantly increased after rapid pacing but was significantly lower with ARB + ACEI than with ARB or ACEI alone. The collagen volume fraction and mRNA levels of collagen I and III, which were increased by rapid pacing, were significantly lower with ARB + ACEI than with ARB or ACEI alone. Thus ARB + ACEI prevents myocardial fibrosis and decreases LV stiffness during the progression of CHF compared with ARB or ACEI alone.

Sign in / Sign up

Export Citation Format

Share Document